...
首页> 外文期刊>BMC Medical Ethics >Ethical values supporting the disclosure of incidental and secondary findings in clinical genomic testing: a qualitative study
【24h】

Ethical values supporting the disclosure of incidental and secondary findings in clinical genomic testing: a qualitative study

机译:支持临床基因组测试中涉及偶然和中学结果的伦理值:定性研究

获取原文
           

摘要

Incidental findings (IFs) and secondary findings (SFs), being results that are unrelated to the diagnostic question, are the subject of an important debate in the practice of clinical genomic medicine. Arguments for reporting these results or not doing so typically relate to the principles of autonomy, non-maleficence and beneficence. However, these principles frequently conflict and are insufficient by themselves to come to a conclusion. This study investigates empirically how ethical principles are considered when actually reporting IFs or SFs and how value conflicts are weighed. A qualitative focus group study has been undertaken, including a multidisciplinary group of professionals from Belgian centres for medical genetics. The data were analysed thematically. All eight Belgian centres participated in this study. Ethical values were frequently referred to for disclosure policies on IFs and SFs. Participants invoked respect for patient autonomy to support the disclosure of IFs and opt-out options for IFs and SFs, non-maleficence for the professional delineation of reportable IFs and opt-out options for IFs and SFs and (the particular scope of) beneficence for the mandatory reporting of actionable IFs, the delineation of reportable IFs and a current decline of actively pursued SFs. Professional assumptions about patients’ genetic literacy were an important factor in the weighing of values. In line with the traditional bioethical discourse, the mandatory reporting of actionable IFs might be interpreted as a “technological, soft paternalism”. Restricting patients’ choices might be acceptable, but then its motives should be valid and its beneficent outcomes highly plausible. Hence, the presuppositions of technological, soft paternalism - patients’ inability to make informed decisions, normative rationality, the efficacy of beneficent outcomes and the delineated spectrum of beneficence - should be approached critically. Moreover, distributive justice should be considered an important value in the delineation of the current scope of the ethical debate on IFs and SFs. This study of guiding values may stimulate the debate on the ethical grounds for a solid policy on IFs and SFs internationally.
机译:附带调查结果(IFS)和二次调查结果(SFS),与诊断问题无关的结果是临床基因组实践中重要争论的主题。报告这些结果或不这样做的论据通常涉及自治,非恶意和益性的原则。然而,这些原则经常发生冲突,并且不足以得出结论。本研究证明,在实际报告IFS或SFS以及权衡重值冲突的情况下,如何考虑如何考虑道德原则。已经进行了一个定性焦点小组研究,包括来自比利时中心的医学遗传学中心的多学科专业人士组。主题分析数据。所有八个比利时中心参加了这项研究。常规称为IFS和SFS的披露政策。参与者尊重患者自主权,支持披露IFS和SFS的退出选项,非恶意为专业划清有报告拟议的专业划分,以及IFS和SFS的退出选项以及(特定范围)惠益强制性报告可行的IFS,可报告IFS的划定和积极追求的SFS的目前下降。关于患者的遗传素养的专业假设是价值称重的重要因素。符合传统的生态话语,强制性报告可行的IFS可能被解释为“技术,软体动物”。限制患者的选择可能是可以接受的,但随后其动机应该是有效的,其受益的结果非常合理。因此,技术,软体动物 - 患者无法做出明智的决策,规范性理性,受益性结果的有效性以及划定的受益范围的患者的预设,应当批判自要。此外,分配司法应该被认为是划定关于IFS和SFS的伦理辩论范围的重要价值。这项指导价值观的研究可以刺激关于IFS和SFS的实体政策的伦理理由的辩论。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号